Quralis Included in the Fierce Biotech 2020 Fierce 15 List

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2020-10-10

Source: Viva Biotech

[Abstract]:Quralis was included in the Annual Fierce Biotechnology's 2020 Fierce 15 List.

Massachusetts, U.S. - on September 29, 2020, the industry-renowned annual fierce biotechnology's 2020 fierce 15 list was released. Quralis, a platform company invested and incubated by Viva BioInnovator was included in the list. As a biotech company focused on the precise treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases, Quralis continues to promote the development of new therapies for ALS and genetically related frontotemporal dementia (FTD). Up to now, there is no effective treatment for neurodegenerative diseases on the market.

Previous Page：Arthrosi Therapeutics Completed Round C Financing to Accelerate the Development of Novel Gout Treatments Next Page：Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

Back

Media contact: vivapr@vivabiotech.com